Evidence map›Paper›PMID 41051536›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2026

Texture analysis of [

Louise Rice, Balaji Ganeshan, Simon Wan, Shih-Hsin Chen, David M L Lilburn, Manuel Rodriguez-Justo, Stuart Taylor, Robert I Shortman, Raymond Endozo, Saif Khan and 6 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Louise Rice *Institute of Nuclear Medicine, University College London Hospital (UCLH), London, UK.
Balaji Ganeshan *Institute of Nuclear Medicine, Division of Medicine, University College London (UCL), London, UK.
Simon Wan *Institute of Nuclear Medicine, Division of Medicine, University College London (UCL), London, UK.
Shih-Hsin ChenDepartment of Nuclear Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
David M L LilburnPET Centre, School of Biomedical Engineering & Imaging Sciences, St Thomas' Hospital, King's College London (KCL), London, UK.
Manuel Rodriguez-JustoSurgery and Cancer Board, Imaging Division, University College Hospital (UCH), University College London Hospitals (UCLH) NHS Foundation Trust, London, UK.
Stuart TaylorCentre of Medical Imaging, Division of Medicine, University College London (UCL), London, UK.
Robert I ShortmanInstitute of Nuclear Medicine, University College London Hospital (UCLH), London, UK.
Raymond EndozoInstitute of Nuclear Medicine, University College London Hospital (UCLH), London, UK.
Saif KhanSurgery and Cancer Board, Imaging Division, University College Hospital (UCH), University College London Hospitals (UCLH) NHS Foundation Trust, London, UK.
Luke R HoyInstitute of Nuclear Medicine, Division of Medicine, University College London (UCL), London, UK.
Daren FrancisDepartment of Colorectal Surgery, Barnet and Chase Farm Hospitals, Royal Free London NHS Foundation Trust, London, UK.
Tan ArulampalamDepartment of Surgery, Department of Clinical Oncology, Colchester General Hospital, East Suffolk and North Essex NHS Foundation Trust, Essex, UK.
Nicholas Reay-JonesColorectal Surgery, Queen Elizabeth II Hospital, East and North Hertfordshire NHS Trust, Hertfordshire, UK.
Kenneth A Miles *Institute of Nuclear Medicine, Division of Medicine, University College London (UCL), London, UK.
Ashley M Groves *Institute of Nuclear Medicine, Division of Medicine, University College London (UCL), London, UK. a.groves@ucl.ac.uk.ORCID 0000-0003-0358-0795

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleIt is challenging to identify which patients with Stage II colorectal cancer (T3N0M0 and T4N0M0) are at high risk of recurrence and might benefit from additional therapies. This preliminary study examines whether multiparametric [ MATERIALS AND

methodsThis multicentre, prospective observational study included 66 patients (41 male, 25 female, mean age 69.1 ± 10.3yrs) with biopsy-proven Stage II colorectal cancer who underwent [

results49 patients survived the follow up period, with a mean overall survival of 88.4 (± 42.3 months). Univariate analysis showed no significant survival association with clinical variables such as patient sex (p = 0.295), age (p = 0.085), tumour side (p = 0.662), location (p = 0.848) or volume (p = 0.782), or high-risk histopathological metrics including low number lymph node sampling (p = 0.363), perineural, lymphovascular or extramural tumour invasion (p = 0.196), poor tumour differentiation (p = 0.372), and tumour perforation (p = 0.475). No significant survival difference was observed between T3 and T4-stages (p = 0.748). An increased mortality risk was observed for patients with a pixel mean intensity < 20.390 on CT texture (coarse texture scale), HR: 3.40 (1.36-8.49); p = 0.005, and where SUVmax ≥ 25.560 g/mL on [

conclusionMultiparametric [

Indexed as

Colorectal NeoplasmsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDG PET/CTColorectal cancerCT textureSurvival

Identifiers

PMID41051536
PMCPMC12860759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.